A detailed history of Virginia Retirement Systems Et Al transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Virginia Retirement Systems Et Al holds 82,300 shares of IOVA stock, worth $190,936. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,300
Holding current value
$190,936
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 20, 2025

BUY
$1.7 - $3.97 $139,910 - $326,731
82,300 New
82,300 $178,000
Q1 2025

Jul 16, 2025

BUY
$3.33 - $7.79 $103,230 - $241,490
31,000 New
31,000 $103,000
Q1 2023

Jul 11, 2023

SELL
$5.53 - $8.22 $38,157 - $56,718
-6,900 Reduced 38.12%
11,200 $68,000
Q4 2022

May 17, 2023

SELL
$5.62 - $10.0 $45,522 - $81,000
-8,100 Reduced 30.92%
18,100 $116 Million
Q3 2022

May 16, 2023

BUY
$9.53 - $13.11 $249,685 - $343,482
26,200 New
26,200 $251 Million
Q2 2021

Aug 13, 2021

SELL
$16.33 - $33.07 $129,006 - $261,253
-7,900 Closed
0 $0
Q1 2021

Apr 30, 2021

SELL
$28.67 - $52.59 $48,739 - $89,403
-1,700 Reduced 17.71%
7,900 $250,000
Q4 2020

Feb 16, 2021

BUY
$28.04 - $50.26 $11,216 - $20,104
400 Added 4.35%
9,600 $445,000
Q3 2020

Nov 12, 2020

SELL
$27.75 - $36.3 $263,625 - $344,850
-9,500 Reduced 50.8%
9,200 $303,000
Q2 2020

Aug 12, 2020

SELL
$27.21 - $41.0 $51,699 - $77,900
-1,900 Reduced 9.22%
18,700 $513,000
Q1 2020

May 12, 2020

BUY
$19.54 - $38.85 $5,862 - $11,655
300 Added 1.48%
20,600 $617,000
Q4 2019

Jan 27, 2020

BUY
$17.95 - $29.41 $364,385 - $597,023
20,300 New
20,300 $562,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $366M
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.